Inflamasi Jantung pada Diabetes: Tinjauan Naratif mengenai Siklus Metabolik-Imun dan Cedera Miokardium Cardiac Inflammation in Diabetes

Bagikan artikel ini Bagikan via WhatsApp

Statistik artikel

Data OJS dan sumber sitasi
Tayangan abstrak20OJS
Unduhan artikel7OJS
Sitasi Crossref—Belum tersedia
Sitasi Google Scholar—Belum terverifikasi

Tayangan dan unduhan adalah aktivitas yang tercatat di OJS; pemrosesan statistik dapat tertunda. Tanda — berarti angka dari sumber tersebut belum tersedia. Cari di Google Scholar

Isi Artikel Utama

Mahfira Fitri
https://orcid.org/0009-0008-8286-2275
Roza Silvia
Cimi Ilmiawati

Abstrak

Latar Belakang: Diabetes melitus merupakan gangguan metabolik yang berhubungan dengan komplikasi kardiovaskular progresif, termasuk kardiomiopati diabetik. Bukti yang semakin berkembang menunjukkan bahwa inflamasi jantung menghubungkan stres metabolik dengan cedera miokardium dan remodeling struktural. Namun, hubungan temporal dan kausal di antara proses umpan balik cedera miokardium terhadap stres metabolic belum sepenuhnya terbukti. Tujuan: Review ini bertujuan merangkum bukti terkini mengenai mekanisme yang mendasari inflamasi jantung pada diabetes serta mengusulkan kerangka integratif yang menghubungkan respon metabolik, imun, dan miokardium. Metode: Review naratif terstruktur dilakukan dengan mengacu pada prinsip Scale for the Assessment of Narrative Review Articles (SANRA). Literatur yang dipublikasikan dari Januari 2020 hingga Juli 2026 diidentifikasi melalui PubMed, Scopus, Web of Science, dan ScienceDirect menggunakan kombinasi istilah MeSH dan free-text terkait diabetes, kardiomiopati diabetik, inflamasi, stres oksidatif, disfungsi mitokondria, inflamasom NLRP3, dan pyroptosis. Hasil: Hiperglikemia kronis dan lipotoksisitas meningkatkan pembentukan advanced glycation end products, stres oksidatif, dan disfungsi mitokondria yang mengaktivasi pensinyalan RAGE, TLR4, NF-κB, dan inflamasom NLRP3. Jalur tersebut mendorong komunikasi inflamasi antara makrofag, kardiomiosit, dan fibroblas, yang berkontribusi terhadap pyroptosis, hipertrofi, fibrosis, dan disfungsi miokardium. Cedera jaringan yang menetap dapat semakin memperkuat inflamasi lokal melalui damage-associated molecular patterns dan sinyal bahaya mitokondria. Namun, bukti yang mendukung adanya mekanisme umpan balik positif tertutup secara lengkap, terutama jalur kausal dari cedera miokardium kembali menuju stres metabolik awal, masih terbatas. Kesimpulan: Siklus metabolik–imun–cedera miokardium diusulkan sebagai hipotesis konseptual untuk menjelaskan persistensi dan kemungkinan amplifikasi inflamasi jantung pada diabetes. Pemahaman terhadap mekanisme ini dapat mendukung identifikasi target terapeutik baru untuk mencegah progresi kardiomiopati diabetik.

Rincian Artikel

Bagian

Review Article

Cara Mengutip

Inflamasi Jantung pada Diabetes: Tinjauan Naratif mengenai Siklus Metabolik-Imun dan Cedera Miokardium: Cardiac Inflammation in Diabetes. (2026). Journal of Pharmaceutical and Sciences, 9(4), 3478-3487. https://doi.org/10.36490/journal-jps.com.v9i4.1826

Referensi

[1] Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res 2020;126:1501–25. https://doi.org/10.1161/CIRCRESAHA.120.315913.

[2] Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol 2020;17:585–607. https://doi.org/10.1038/s41569-020-0339-2.

[3] Pan KL, Hsu YC, Chang ST, Chung CM, Lin CL. The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools. Int J Mol Sci 2023;24. https://doi.org/10.3390/ijms24108604.

[4] Ramesh P, Yeo JL, Brady EM, McCann GP. Role of inflammation in diabetic cardiomyopathy. Ther Adv Endocrinol Metab 2022;13. https://doi.org/10.1177/20420188221083530.

[5] Peng ML, Fu Y, Wu CW, Zhang Y, Ren H, Zhou SS. Signaling Pathways Related to Oxidative Stress in Diabetic Cardiomyopathy. Front Endocrinol (Lausanne) 2022;13. https://doi.org/10.3389/fendo.2022.907757.

[6] Song M, Dai H, Zhou Q, Meng X. The immunology of diabetic cardiomyopathy. Front Endocrinol (Lausanne) 2025;16. https://doi.org/10.3389/fendo.2025.1542208.

[7] De Blasio MJ, Ritchie RH. Inflammatory signalling in diabetic cardiomyopathy: molecular mechanisms and potential therapeutic strategies. Nat Rev Cardiol 2026. https://doi.org/10.1038/s41569-026-01274-y.

[8] Huo S, Wang M, Du M, Ren B, Yang T, Peng L, et al. Macrophage-derived S100A9 promotes diabetic cardiomyopathy by disturbing mitochondrial quality control via STAT3 activation. Int J Biol Sci 2025;21:3061–80. https://doi.org/10.7150/ijbs.111128.

[9] De Geest B, Mishra M. Role of Oxidative Stress in Diabetic Cardiomyopathy. Antioxidants 2022;11. https://doi.org/10.3390/antiox11040784.

[10] Peng ML, Fu Y, Wu CW, Zhang Y, Ren H, Zhou SS. Signaling Pathways Related to Oxidative Stress in Diabetic Cardiomyopathy. Front Endocrinol (Lausanne) 2022;13. https://doi.org/10.3389/fendo.2022.907757.

[11] Wang Y, Luo W, Han J, Khan ZA, Fang Q, Jin Y, et al. MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy. Nature Communications 2020;11. https://doi.org/10.1038/s41467-020-15978-3.

[12] Chen X, Qian J, Liang S, Qian J, Luo W, Shi Y, et al. Hyperglycemia activates FGFR1 via TLR4/c-Src pathway to induce inflammatory cardiomyopathy in diabetes. Acta Pharm Sin B 2024;14:1693–710. https://doi.org/10.1016/j.apsb.2024.01.013.

[13] Zhang S, Zhu X, Chen Y, Wen Z, Shi P, Ni Q. The role and therapeutic potential of macrophages in the pathogenesis of diabetic cardiomyopathy. Front Immunol 2024;15. https://doi.org/10.3389/fimmu.2024.1393392.

[14] Nakamura M. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy. Journal of Pharmacy and Pharmaceutical Sciences 2024;27. https://doi.org/10.3389/jpps.2024.12568.

[15] Zhan J, Jin K, Xie R, Fan J, Tang Y, Chen C, et al. AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation. Circulation 2024;149:1102–20. https://doi.org/10.1161/CIRCULATIONAHA.123.065546.

[16] Hao J, Zhou J, Hu S, Zhang P, Wu H, Yang J, et al. RTA 408 ameliorates diabetic cardiomyopathy by activating Nrf2 to regulate mitochondrial fission and fusion and inhibiting NF-jB-mediated inflammation. Am J Physiol Cell Physiol 2024;326:C331–47. https://doi.org/10.1152/ajpcell.00467.2023.

[17] Rostami A, Palomer X, Pizarro-Delgado J, Barroso E, Valenzuela-Alcaraz B, Crispi F, et al. PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy. Pharmacol Res 2024;210. https://doi.org/10.1016/j.phrs.2024.107515.

[18] Cohen CD, De Blasio MJ, Farrugia GE, Dona MSI, Hsu I, Prakoso D, et al. Mapping the cellular and molecular landscape of cardiac non-myocytes in murine diabetic cardiomyopathy. IScience 2023;26. https://doi.org/10.1016/j.isci.2023.107759.

[19] Sun Y, Ding S. Nlrp3 inflamasome in diabetic cardiomyopathy and exercise intervention. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms222413228.

[20] Ding P, Song Y, Yang Y, Zeng C. NLRP3 inflamasome and pyroptosis in cardiovascular diseases and exercise intervention. Front Pharmacol 2024;15. https://doi.org/10.3389/fphar.2024.1368835.

[21] Huang Y, Xu W, Zhou R. NLRP3 inflamasome activation and cell death. Cell Mol Immunol 2021;18:2114–27. https://doi.org/10.1038/s41423-021-00740-6.

[22] Seoane PI, Lee B, Hoyle C, Yu S, Lopez-Castejon G, Lowe M, et al. The NLRP3–inflamasome as a sensor of organelle dysfunction. Journal of Cell Biology 2020;219. https://doi.org/10.1083/JCB.202006194.

[23] Zeng C, Duan F, Hu J, Luo B, Huang B, Lou X, et al. NLRP3 inflamasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol 2020;34. https://doi.org/10.1016/j.redox.2020.101523.

[24] Zhang T, Ding S, Wang R. Research progress of mitochondrial mechanism in NLRP3 inflamasome activation and exercise regulation of NLRP3 inflamasome. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms221910866.

[25] Yan M, Li L, Wang Q, Shao X, Luo Q, Liu S, et al. The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflamasome activation. Biomedicine and Pharmacotherapy 2022;148. https://doi.org/10.1016/j.biopha.2022.112709.

[26] Li Y, Luo M, Chang Q, Cao S, Wang Y, Chen Z, et al. High-intensity interval training and moderate-intensity continuous training alleviate vascular dysfunction in spontaneously hypertensive rats through the inhibition of pyroptosis. Heliyon 2024;10. https://doi.org/10.1016/j.heliyon.2024.e39505.

[27] Wang J, Li Y, Li L, Liang H, Ye H, Kang P, et al. Effect of NLRP3 gene knockdown on pyroptosis and ferroptosis in diabetic cardiomyopathy injury. BMC Cardiovasc Disord 2024;24. https://doi.org/10.1186/s12872-024-04010-x.

[28] Li T, Wang P, Wang X, Liu Z, Zhang Z, Zhang Y, et al. Inflammation and Insulin Resistance in Diabetic Chronic Coronary Syndrome Patients. Nutrients 2023;15. https://doi.org/10.3390/nu15122808.

[29] Kufazvinei TTJ, Chai J, Boden KA, Channon KM, Choudhury RP. Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes. Cardiovasc Res 2024;120:1241–52. https://doi.org/10.1093/cvr/cvae142.

[30] Nan W, Yin J, Hao W, Meng H, Wu J, Yin X, et al. Cardamonin protects against diabetic cardiomyopathy by activating macrophage NRF2 signaling through molecular interaction with KEAP1. Food Funct 2024;15:11083–95. https://doi.org/10.1039/d4fo03543g.

[31] Wen X, Fan J, Duan X, Zhu X, Bai J, Zhang T. Mitochondrial DNA in Exercise-Mediated Innate Immune Respones. Int J Mol Sci 2025;26. https://doi.org/10.3390/ijms26073069.

[32] Li S, Zhang J, Zhao Y, Kang L, Jie H, Dong B. (Pro)renin receptor aggravates myocardial pyroptosis in diabetic cardiomyopathy through AMPK-NLRP3 pathway. Front Pharmacol 2024;15. https://doi.org/10.3389/fphar.2024.1453647.

[33] Meier DT, de Paula Souza J, Donath MY. Targeting the NLRP3 inflamasome–IL-1β pathway in type 2 diabetes and obesity. Diabetologia 2025;68:3–16. https://doi.org/10.1007/s00125-024-06306-1.

[34] Tan Y, Chen S, Gao T, Wang S, Zhou X, Liu M. Exploring the role of NLRP3 infalmmasome in diabetes: a literature review and bibliometric analysis. Front Endocrinol (Lausanne) 2024;15. https://doi.org/10.3389/fendo.2024.1443798.

[35] Cabral JE, Wu A, Zhou H, Pham MA, Lin S, McNulty R. Targeting the NLRP3 inflamasome for inflammatory disease therapy. Trends Pharmacol Sci 2025;46:503–19. https://doi.org/10.1016/j.tips.2025.04.007.

[36] Chen Y, Ye X, Escames G, Lei W, Zhang X, Li M, et al. The NLRP3 inflamasome: contributions to

Artikel paling banyak dibaca berdasarkan penulis yang sama